Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
((1s,3s)-3-(7-amino-2H-2,3,5,6-tetraazabenzo[cd]azulen-2-yl)cyclobutyl)methyl tetrahydrogen triphosphate
-
-
(-)-epigallocatechin-3-gallate
-
exposure to (-)-epigallocatechin-3-gallate reduces cellular proliferation and induced apoptosis in both MCF-7 and HL60 cells in vitro, although TERT mRNA expression is decreased only in MCF-7 cells
(2-amino-5-chlorophenyl)(2-chlorophenyl)methanone
-
-
(2-amino-5-chlorophenyl)(2-fluorophenyl)methanone
-
-
(2-amino-5-chlorophenyl)(phenyl)methanone
-
-
(4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one
-
(4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one
-
-
(R)-9-(2-phosphonomethoxypropyl)adenine
-
-
([[(2R,5R)-5-(6-amino-7H-purin-7-yl)-2,5-dihydrofuran-2-yl]oxy]methyl)phosphonic acid
-
-
([[(2R,5R)-5-(6-amino-7H-purin-7-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxy]methyl)phosphonic acid
-
-
([[(2S,5S)-5-(6-amino-7H-purin-7-yl)-2,5-dihydrofuran-2-yl]oxy]methyl)phosphonic acid
-
-
1,10-di-2',3'-dideoxy-3'-thiacytidine-decanoate
-
-
1,10-di-3'-azido-2',3'-dideoxythymidine-decanoate
-
-
1,10-di-3'-fluoro-2',3'-dideoxythymidine-decanoate
-
-
1,12-di-2',3'-dideoxy-3'-thiacytidine-dodecanoate
-
-
1,12-di-3'-azido-2',3'-dideoxythymidine-dodecanoate
-
-
1,12-di-3'-fluoro-2',3'-dideoxythymidine-dodecanoate
-
-
1,14-di-2',3'-dideoxy-3'-thiacytidine-tetradecanoate
-
-
1,14-di-3'-azido-2',3'-dideoxythymidine-tetradecanoate
-
-
1,14-di-3'-fluoro-2',3'-dideoxythymidine-tetradecanoate
-
-
1,2-bis(2-oxopropoxy)anthracene-9,10-dione
-
-
1,2-bis[(3-oxobutan-2-yl)oxy]anthracene-9,10-dione
-
-
1,4-di-2',3'-dideoxy-3'-thiacytidine-succinate
-
-
1-benzyl-4-(2,6-difluorophenyl)-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-1H-pyrrolo[2,3-b]quinoline-3-carbonitrile
-
-
1-benzyl-4-(2,6-dimethylphenyl)-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-1H-pyrrolo[2,3-b]quinoline-3-carbonitrile
-
-
1-benzyl-4-(3-chlorophenyl)-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-1H-pyrrolo[2,3-b]quinoline-3-carbonitrile
-
-
1-benzyl-4-(4-fluorophenyl)-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-1H-pyrrolo[2,3-b]quinoline-3-carbonitrile
-
-
1-benzyl-7,7-dimethyl-4-(4-nitrophenyl)-5-oxo-5,6,7,8-tetrahydro-1H-pyrrolo[2,3-b]quinoline-3-carbonitrile
-
-
1-benzyl-7,7-dimethyl-5-oxo-4-phenyl-5,6,7,8-tetrahydro-1H-pyrrolo[2,3-b]quinoline-3-carbonitrile
-
-
1-benzyl-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-1H-pyrrolo[2,3-b]quinoline-3-carbonitrile
-
-
1-butyl-4-[2-fluoro-4-(trifluoromethyl)phenyl]-5-oxo-1,5-dihydroindeno[1,2-b]pyrrolo[3,2-e]pyridine-3-carbonitrile
-
-
1-tert-butyl-5-formyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile
-
-
1-[2',5'-bis-O-(t-butyldimethylsilyl)beta-D-ribofuranosyl]-3'-spiro-5''-(4''amino-1'',2''-oxathiole-2'',2''-dioxide)-3-ethylthymine
-
-
12-(deoxyadenosin-N1-yl)nevirapine
-
-
12-(deoxyadenosin-N6-yl)nevirapine
-
-
12-(deoxycytidin-N3-yl)nevirapine
-
-
12-(deoxyguanosin-O6-yl)nevirapine
-
-
12-hydroxy-nevirapine
-
-
2',3'-dehydro-2',3'-deoxythymidine triphosphate
2',3'-Didehydro-2',3'-dideoxycytidine 5'-triphosphate
-
-
2',3'-didehydro-2',3'-dideoxythymidine
-
-
2',3'-didehydro-2',3'-dideoxythymidine 5'-triphosphate
-
strong but nonspecific inhibitor
2',3'-dideoxy-2',3'-dehydrothymidine 5'-triphosphate
2',3'-dideoxy-3'-thiacytidine
-
-
2',3'-dideoxy-5-fluoro-3'-thiacytidine
-
-
2',3'-dideoxycytidine
-
-
2',3'-dideoxyguanosine triphosphate
-
-
2',3'-dideoxythymidine 5'-triphosphate
2',5'-Oligoadenylate
-
mixed type inhibition, not strictly competitive with dTTP. Inhibition is most dramatic in the absence of sulfhydryl reagents and is reduced when either dithiothreitol or 2-mercaptoethanol are included in the reaction. Partial protection at 0.1 mM dithiothreitol, significant protection at 1 mM or above
2'-deoxyxylofuranosylthymidine 5'-triphosphate
-
Mn2+ is requisite for the compound to exhibit inhibition, competitive with dTTP
2'-fluoro-N-cyclobutyladenosine triphosphate
-
-
2,4,6-trichloroquinoline
-
-
2,7-dihydroxy-2,4,6-cyclo-heptatrien-1-one
-
beta-thujaplicinol analogue. Compound has no effect on polymerase-dependent RNase H cleavages but significantly affects the rates of polymerase-independent RNase H cleavages. In a model, the compoouind binds to the RNase H active site after the primary polymerase-dependent RNase H cleavage has occurred and stabilizes the 3'-end of the DNA primer in the polymerase active site thus blocking the enzyme's ability to carry out the polymerase-independent cleavages
2-acetyl-4-[4-(dimethylamino)phenyl]indeno[1,2-b]pyrrolo[3,2-e]pyridin-5(1H)-one
-
-
2-amino-3'-azido-2',3'-dideoxy-N,N-dimethyladenosine 5'-triphosphate
-
-
2-amino-4-(3-benzoylphenyl)thiazole-5-carboxamide
-
2-amino-4-(3-bromo-4-chlorophenyl)thiazole-5-carboxamide
-
2-amino-4-(3-chlorophenyl)thiazole-5-carboxamide
-
2-amino-4-(3-iodophenyl)thiazole-5-carboxamide
-
2-amino-4-(3-phenylphenyl)thiazole-5-carboxamide
-
2-amino-4-phenylthiazole-5-carboxamide
-
2-hydroxy-6-pentadecylbenzoic acid
-
isolated from the CH2Cl2 extracts of the sacrotestas of Ginkgo biloba
2-hydroxy-6-[(8Z)-pentadec-8-en-1-yl]benzoic acid
-
isolated from the CH2Cl2 extracts of the sacrotestas of Ginkgo biloba
2-naphthalenesulfonic acid
-
in the ternary enzyme-DNA-inhibitor complex, incorporation of the next nucleotide onto the primer is blocked. KM-1 can bind to the enzyme in both the absence and presence of DNA but weakens the affinity for DNA 140fold so that it favors DNA dissociation. KM-1 distorts enzyme conformation and misaligns DNA at the active site
2-pyridin-3-yl-1-(3,4,5-trimethoxybenzoyl)-1H-benzimidazole
-
-
2-pyridin-3-yl-1H-benzimidazole
-
-
2-[(10Z)-heptadec-10-en-1-yl]-6-hydroxybenzoic acid
-
isolated from the CH2Cl2 extracts of the sacrotestas of Ginkgo biloba
2-[2-(4-bromophenyl)-2-oxoethoxy]-9,10-dioxo-9,10-dihydroanthracen-1-yl acetate
-
-
2-[2-(biphenyl-4-yl)-2-oxoethoxy]-9,10-dioxo-9,10-dihydroanthracen-1-yl acetate
-
-
3'-azido-2',3'-dideoxy-2,6-diaminopurine-beta-D-ribofuranosyl 5'-triphosphate
-
-
3'-azido-2',3'-dideoxy-2-amino-6-chloropurine-beta-D-ribofuranosyl 5'-triphosphate
-
-
3'-azido-2',3'-dideoxy-2-amino-6-methoxypurine-beta-D-ribofuranosyl 5'-triphosphate
-
-
3'-azido-2',3'-dideoxy-2-amino-6-N-allylaminopurine-beta-D-ribofuranosyl 5'-triphosphate
-
-
3'-azido-2',3'-dideoxyadenosine triphosphate
-
-
3'-azido-2',3'-dideoxyguanosine triphosphate
-
-
3'-azido-2',3'-dideoxythymidine
-
-
3'-Azido-2',3'-dideoxythymidine 5'-diphosphate
-
-
3'-Azido-2',3'-dideoxythymidine 5'-triphosphate
3'-azido-2',3'-dideoxythymidine-5'-triphosphate
-
3'-azido-3'-deoxythymidine
3'-azido-3'deoxythymidine 5'-triphosphate
3'-deoxyadenosine
-
inhibits HIV-1 proviral DNA synthesis in human macrophages more efficiently than in CD4+ T cells
3'-dideoxythymidine triphosphate
-
3'-fluoro-2',3'-dideoxythymidine
-
-
3'-gluoro-5'-(2-valyloxypropanoyl)-2',3'-dideoxyguanosine
-
-
3'-hydroxymethyl 2'-dATP
-
highly specific inhibitor
3'-hydroxymethyl 2'-dCTP
-
highly specific inhibitor
3'-hydroxymethyl 2'-dGTP
-
highly specific inhibitor
3'-hydroxymethyl 2'-dUTP
-
highly specific inhibitor
3,5-dimethyl-4-[[2-([(3R)-1-[(pyridin-4-yl)methyl]pyrrolidin-3-yl]amino)thieno[3,2-d]pyrimidin-4-yl]oxy]benzonitrile
-
exceptionally potent against a wide range of HIV-1 strains carrying single NNRTI-resistant mutations
3,5-dimethyl-4-[[2-([(3S)-1-[(pyridin-4-yl)methyl]pyrrolidin-3-yl]amino)thieno[3,2-d]pyrimidin-4-yl]oxy]benzonitrile
-
-
3,5-dimethyl-4-[[2-([1-[(4-nitrophenyl)methyl]-1,2,3,4-tetrahydropyridin-4-yl]amino)-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl]oxy]benzonitrile
-
-
3,5-dimethyl-4-[[2-([1-[(4-nitrophenyl)methyl]piperidin-4-yl]amino)-5,7-dihydrofuro[3,4-d]pyrimidin-4-yl]oxy]benzonitrile
-
-
3,5-dimethyl-4-[[2-([1-[(4-nitrophenyl)methyl]piperidin-4-yl]amino)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]oxy]benzonitrile
-
-
3,5-dimethyl-4-[[2-([1-[(4-nitrophenyl)methyl]piperidin-4-yl]amino)-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl]oxy]benzonitrile
-
-
3,5-dimethyl-4-[[2-([1-[(4-nitrophenyl)methyl]piperidin-4-yl]amino)-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidin-4-yl]oxy]benzonitrile
-
-
3,5-dimethyl-4-[[2-([1-[(pyridin-4-yl)methyl]azepan-4-yl]amino)thieno[3,2-d]pyrimidin-4-yl]oxy]benzonitrile
-
-
3,5-dimethyl-4-[[2-([1-[(pyridin-4-yl)methyl]azetidin-3-yl]amino)thieno[3,2-d]pyrimidin-4-yl]oxy]benzonitrile
-
-
3,5-dimethyl-4-[[2-([1-[(pyridin-4-yl)methyl]piperidin-4-yl]amino)-5,6,7,8-tetrahydroquinazolin-4-yl]oxy]benzonitrile
-
-
3,5-dimethyl-4-[[2-([1-[(pyridin-4-yl)methyl]piperidin-4-yl]amino)-5,7-dihydrofuro[3,4-d]pyrimidin-4-yl]oxy]benzonitrile
-
-
3,5-dimethyl-4-[[2-([1-[(pyridin-4-yl)methyl]piperidin-4-yl]amino)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]oxy]benzonitrile
-
-
3,5-dimethyl-4-[[2-([1-[(pyridin-4-yl)methyl]piperidin-4-yl]amino)-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl]oxy]benzonitrile
-
-
3,5-dimethyl-4-[[2-([8-[(pyridin-4-yl)methyl]-8-azabicyclo[3.2.1]octan-3-yl]amino)thieno[3,2-d]pyrimidin-4-yl]oxy]benzonitrile
-
-
3-(2,4-dinitrophenylhydrazonomethyl) rifamycin SV
-
-
3-(2-cyanoacetyl)phenyl diethyl phosphate
-
3-(3-chlorophenyl)-3-oxopropanenitrile
-
3-(3-iodophenyl)-3-oxopropanamide
-
3-(3-methylbut-2-en-1-yl)-4-[(3-methylbut-2-en-1-yl)oxy]quinolin-2(1H)-one
-
-
3-([3-bromo-2-oxo-5-[(pyridin-3-yloxy)methyl]-1,2-dihydropyridin-4-yl]oxy)-5-chlorobenzonitrile
-
-
3-([3-bromo-2-oxo-5-[(pyridin-4-yloxy)methyl]-1,2-dihydropyridin-4-yl]oxy)-5-chlorobenzonitrile
-
-
3-([3-bromo-5-fluoro-2-oxo-6-[2-(pyridin-4-yl)ethyl]-1,2-dihydropyridin-4-yl]oxy)-5-chlorobenzonitrile
-
-
3-([3-bromo-6-[2-(3-chlorophenyl)ethyl]-5-fluoro-2-oxo-1,2-dihydropyridin-4-yl]oxy)-5-chlorobenzonitrile
-
-
3-([6-[2-(1,3-benzoxazol-2-yl)ethyl]-3-chloro-2-oxo-1,2-dihydropyridin-4-yl]oxy)-5-chlorobenzonitrile
-
-
3-benzoyl-3-oxopropanenitrile
-
3-chloro-5-([3-chloro-2-oxo-6-[2-(pyridin-2-yl)ethyl]-1,2-dihydropyridin-4-yl]oxy)benzonitrile
-
-
3-chloro-5-([3-chloro-2-oxo-6-[2-(pyridin-3-yl)ethyl]-1,2-dihydropyridin-4-yl]oxy)benzonitrile
-
-
3-chloro-5-([3-chloro-2-oxo-6-[2-(pyridin-4-yl)ethyl]-1,2-dihydropyridin-4-yl]oxy)benzonitrile
-
-
3-chloro-5-([3-chloro-6-methyl-2-oxo-5-[2-(pyridin-3-yl)ethyl]-1,2-dihydropyridin-4-yl]oxy)benzonitrile
-
-
3-chloro-5-([3-chloro-6-[2-(3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]-5-fluoro-2-oxo-1,2-dihydropyridin-4-yl]oxy)benzonitrile
-
-
3-chloro-5-([3-chloro-6-[2-(3-chlorophenyl)ethyl]-2-oxo-1,2-dihydropyridin-4-yl]oxy)benzonitrile
-
-
3-chloro-5-([6-[2-(3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]-3-(dimethylamino)-5-fluoro-2-oxo-1,2-dihydropyridin-4-yl]oxy)benzonitrile
-
-
3-chloro-5-[[3-chloro-2-oxo-6-(2-phenylethyl)-1,2-dihydropyridin-4-yl]oxy]benzonitrile
-
-
3-chloro-5-[[3-chloro-5-fluoro-2-oxo-6-(2-phenylethyl)-1,2-dihydropyridin-4-yl]oxy]benzonitrile
-
-
3-chloro-5-[[3-chloro-6-methyl-2-oxo-5-(phenoxymethyl)-1,2-dihydropyridin-4-yl]oxy]benzonitrile
-
-
3-cyclic amine derivative of rifamycin SV
-
0.2 mg/ml, more than 90% inhibition
-
3-pentadecylphenol
-
isolated from the CH2Cl2 extracts of the sacrotestas of Ginkgo biloba
3-phenyl-3-oxopropanenitrile
-
3-piperazinoiminomethyl rifamycin SV
-
-
3-tridecylphenol
-
isolated from the CH2Cl2 extracts of the sacrotestas of Ginkgo biloba
3-[(10Z)-heptadec-10-en-1-yl]phenol
-
isolated from the CH2Cl2 extracts of the sacrotestas of Ginkgo biloba
3-[(3-[[4-(4-cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl]amino]-8-azabicyclo[3.2.1]octan-8-yl)methyl]benzamide
-
-
3-[(3-[[4-(4-cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl]amino]azetidin-1-yl)methyl]benzamide
-
-
3-[(4-[[4-(4-cyano-2,6-dimethylphenoxy)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]piperidin-1-yl)methyl]benzamide
-
-
3-[(4-[[4-(4-cyano-2,6-dimethylphenoxy)-5,7-dihydrofuro[3,4-d]pyrimidin-2-yl]amino]piperidin-1-yl)methyl]benzamide
-
-
3-[(4-[[4-(4-cyano-2,6-dimethylphenoxy)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-yl]amino]piperidin-1-yl)methyl]benzamide
-
-
3-[(4-[[4-(4-cyano-2,6-dimethylphenoxy)-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]amino]piperidin-1-yl)methyl]benzamide
-
-
3-[(4-[[4-(4-cyano-2,6-dimethylphenoxy)-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidin-2-yl]amino]piperidin-1-yl)methyl]benzamide
-
-
3-[(4-[[4-(4-cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl]amino]azepan-1-yl)methyl]benzamide
-
-
3-[(5-benzyl-3-bromo-2-oxo-1,2-dihydropyridin-4-yl)oxy]-5-chlorobenzonitrile
-
-
3-[(5-benzyl-3-bromo-6-methyl-2-oxo-1,2-dihydropyridin-4-yl)oxy]-5-chlorobenzonitrile
-
-
3-[(8Z)-pentadec-8-en-1-yl]phenol
-
isolated from the CH2Cl2 extracts of the sacrotestas of Ginkgo biloba
3-[11-(ethoxycarbonyl)-1,7,9,10,11,12-hexahydro-3,2-(metheno)-10-azaazuleno[1',8',7',6':3,4,5]cyclopenta[6,7]fluoreno[2,1,9,8-fghij]benzo[cd]cyclopenta[mno]acephenanthrylen-9-yl]-1-methylpyridinium
-
pyridinium fullerene derivative, 50% cytotoxicity above 0.05 mM
3-[6-bromo-3-[2-(3,4-dihydroisoquinolin-2(1H)-yl)-2-oxoethyl]-2-fluorophenoxy]-5-chlorobenzonitrile
-
-
3-[[(3R)-3-[[4-(4-cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl]amino]pyrrolidin-1-yl]methyl]benzamide
-
exceptionally potent against a wide range of HIV-1 strains carrying single NNRTI-resistant mutations. Favorable pharmacokinetic properties with an oral bioavailability of 30.96% and a half-life of 11.1 h.Ppromising anti-HIV-1 drug candidate with potent antiviral activities and desirable drug-like properties.
3-[[(3S)-3-[[4-(4-cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl]amino]pyrrolidin-1-yl]methyl]benzamide
-
-
3-[[3-bromo-2-oxo-5-(pyridin-4-ylmethoxy)-1,2-dihydropyridin-4-yl]oxy]-5-chlorobenzonitrile
-
-
4'-ethynyl-2-amino-2'-deoxyadenosine triphosphate
4'-ethynyl-2-fluoro-2'-deoxyadenosine
-
a translocation defective RT inhibitor, able to inhibit both WT and multi-drug resistant strains of HIV several orders of magnitude, modeling of the ternary complex of HIV-1 RT/DNA/inhibitor, overview. The 4'-ethynyl group is stabilized in a hydrophobic pocket formed by enzyme residues Ala114, Tyr115, Phe160, Met184, and the aliphatic segment of Asp185
4'-ethynyl-2-fluoro-2'-deoxyadenosine triphosphate
4-((4-((4-(4-cyano-2,6-dimethylphenoxy)-5,7-dihydrofuro-[3,4-d]pyrimidin-2-yl)amino)piperidin-1-yl)methyl)benzamide
-
-
-
4-(3-benzoylphenyl)thiazole-5-carboxamide
-
4-(3-bromo-4-chlorophenyl)-1H-imidazole-5-carboxamide
-
4-(3-bromo-4-chlorophenyl)thiazole-5-carboxamide
-
4-(3-chlorophenyl)-1H-imidazole-5-carboxamide
-
4-(3-iodophenyl)-3-oxobutanenitrile
-
4-([2-[(1-[[4-(methanesulfonyl)phenyl]methyl]-1,2,3,4-tetrahydropyridin-4-yl)amino]-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl]oxy)-3,5-dimethylbenzonitrile
-
-
4-([2-[(1-[[4-(methanesulfonyl)phenyl]methyl]azepan-4-yl)amino]thieno[3,2-d]pyrimidin-4-yl]oxy)-3,5-dimethylbenzonitrile
-
-
4-([2-[(1-[[4-(methanesulfonyl)phenyl]methyl]azetidin-3-yl)amino]thieno[3,2-d]pyrimidin-4-yl]oxy)-3,5-dimethylbenzonitrile
-
-
4-([2-[(1-[[4-(methanesulfonyl)phenyl]methyl]piperidin-4-yl)amino]-5,6,7,8-tetrahydroquinazolin-4-yl]oxy)-3,5-dimethylbenzonitrile
-
-
4-([2-[(1-[[4-(methanesulfonyl)phenyl]methyl]piperidin-4-yl)amino]-5,7-dihydrofuro[3,4-d]pyrimidin-4-yl]oxy)-3,5-dimethylbenzonitrile
-
-
4-([2-[(1-[[4-(methanesulfonyl)phenyl]methyl]piperidin-4-yl)amino]-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]oxy)-3,5-dimethylbenzonitrile
-
-
4-([2-[(1-[[4-(methanesulfonyl)phenyl]methyl]piperidin-4-yl)amino]-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl]oxy)-3,5-dimethylbenzonitrile
-
-
4-([2-[(1-[[4-(methanesulfonyl)phenyl]methyl]piperidin-4-yl)amino]-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidin-4-yl]oxy)-3,5-dimethylbenzonitrile
-
-
4-([2-[(8-[[4-(methanesulfonyl)phenyl]methyl]-8-azabicyclo[3.2.1]octan-3-yl)amino]thieno[3,2-d]pyrimidin-4-yl]oxy)-3,5-dimethylbenzonitrile
-
-
4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
-
-
4-phenyl-1H-imidazole-5-carboxamide
-
4-phenylthiazole-5-carboxamide
-
4-[(2-[[(3R)-1-[[4-(methanesulfonyl)phenyl]methyl]pyrrolidin-3-yl]amino]thieno[3,2-d]pyrimidin-4-yl)oxy]-3,5-dimethylbenzonitrile
-
-
4-[(2-[[(3S)-1-[[4-(methanesulfonyl)phenyl]methyl]pyrrolidin-3-yl]amino]thieno[3,2-d]pyrimidin-4-yl)oxy]-3,5-dimethylbenzonitrile
-
-
4-[(3,5-dimethylphenyl)sulfanyl]quinolin-2(1H)-one
-
-
4-[(3-[[4-(4-cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl]amino]-8-azabicyclo[3.2.1]octan-8-yl)methyl]benzamide
-
-
4-[(3-[[4-(4-cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl]amino]-8-azabicyclo[3.2.1]octan-8-yl)methyl]benzene-1-sulfonamide
-
-
4-[(3-[[4-(4-cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl]amino]azetidin-1-yl)methyl]benzamide
-
-
4-[(3-[[4-(4-cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl]amino]azetidin-1-yl)methyl]benzene-1-sulfonamide
-
-
4-[(4-[[4-(4-cyano-2,6-dimethylphenoxy)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]piperidin-1-yl)methyl]benzamide
-
-
4-[(4-[[4-(4-cyano-2,6-dimethylphenoxy)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]piperidin-1-yl)methyl]benzene-1-sulfonamide
-
-
4-[(4-[[4-(4-cyano-2,6-dimethylphenoxy)-5,7-dihydrofuro[3,4-d]pyrimidin-2-yl]amino]piperidin-1-yl)methyl]benzamide
-
-
4-[(4-[[4-(4-cyano-2,6-dimethylphenoxy)-5,7-dihydrofuro[3,4-d]pyrimidin-2-yl]amino]piperidin-1-yl)methyl]benzene-1-sulfonamide
-
-
4-[(4-[[4-(4-cyano-2,6-dimethylphenoxy)-5,7-dihydrothieno[3,4-d]pyrimidin-2-yl]amino]piperidin-1-yl)methyl]benzene-1-sulfonamide
-
-
4-[(4-[[4-(4-cyano-2,6-dimethylphenoxy)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-yl]amino]piperidin-1-yl)methyl]benzamide
-
-
4-[(4-[[4-(4-cyano-2,6-dimethylphenoxy)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-yl]amino]piperidin-1-yl)methyl]benzene-1-sulfonamide
-
-
4-[(4-[[4-(4-cyano-2,6-dimethylphenoxy)-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]amino]piperidin-1-yl)methyl]benzamide
-
-
4-[(4-[[4-(4-cyano-2,6-dimethylphenoxy)-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]amino]piperidin-1-yl)methyl]benzene-1-sulfonamide
-
-
4-[(4-[[4-(4-cyano-2,6-dimethylphenoxy)-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidin-2-yl]amino]piperidin-1-yl)methyl]benzamide
-
-
4-[(4-[[4-(4-cyano-2,6-dimethylphenoxy)-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidin-2-yl]amino]piperidin-1-yl)methyl]benzene-1-sulfonamide
-
-
4-[(4-[[4-(4-cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl]amino]azepan-1-yl)methyl]benzamide
-
-
4-[(4-[[4-(4-cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl]amino]azepan-1-yl)methyl]benzene-1-sulfonamide
-
-
4-[6-(4-methylpiperazin-1-yl)pyridin-3-yl]-1-(3-methoxypropyl)-8-(1-methyl-1H-pyrazol-4-yl)-2,5-dihydro-1H-indeno[1,2-d]pyrimidine
-
inhibits HIV-1 reverse transcriptase in a primer extension assay but has no measurable activity against human DNA polymerase gamma at 0.01 mM. It potently inhibits HIV-1 replication in vitro with 1.5 nM 50% effective concentration. The antiviral potency is unaffected by the presence of nonnucleotide RT inhibitor mutations L100I, K103N/Y181C, V106A, or Y188L. Viruses encoding K65R are hypersusceptible to inhibition by the compound, and it retains full activity against viruses encoding M184V. A recombinant virus encoding the RT W153L is highly resistant
4-[[(3R)-3-[[4-(4-cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl]amino]pyrrolidin-1-yl]methyl]benzamide
-
-
4-[[(3R)-3-[[4-(4-cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl]amino]pyrrolidin-1-yl]methyl]benzene-1-sulfonamide
-
-
4-[[(3S)-3-[[4-(4-cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl]amino]pyrrolidin-1-yl]methyl]benzamide
-
-
4-[[(3S)-3-[[4-(4-cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl]amino]pyrrolidin-1-yl]methyl]benzene-1-sulfonamide
-
-
4-[[2-([1-[(4-aminophenyl)methyl]piperidin-4-yl]amino)-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl]oxy]-3,5-dimethylbenzonitrile
-
-
4-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-7,8-dihydroxy-2H-chromen-2-one
-
5-benzyl-6-aminouracil
-
competitive with template-primer
5-tridecylbenzene-1,3-diol
-
isolated from the CH2Cl2 extracts of the sacrotestas of Ginkgo biloba
5-[(8Z)-pentadec-8-en-1-yl]benzene-1,3-diol
-
isolated from the CH2Cl2 extracts of the sacrotestas of Ginkgo biloba
6,6-bieckol
-
selective inhibitor, 96.33% inhibition at 0.01 mM
6-([2-[(4-cyanophenyl)amino]pyrimidin-4-yl]amino)-5,7-dimethylnaphthalene-2-carbonitrile
-
compound has potency below 10 nM towards wild-type HIV-1 and viral variants containing the clinically important Y181C and K103N/Y181C mutations, greater activity than efavirenz particularly towards the K103N-bearing variant, normal cytotoxicity, and solubility
6-([4-[(4-cyanophenyl)amino]-1,3,5-triazin-2-yl]amino)-5,7-dimethylnaphthalene-2-carbonitrile
6-chloro-1-(2,6-dichlorobenzyl)-1,3-dihydro-2H-benzimidazol-2-one
-
-
6-chloro-4-(2-fluorophenyl)quinolin-2(1H)-one
-
-
6-chloro-4-(3,5-dimethylphenoxy)quinolin-2(1H)-one
-
-
6-chloro-4-(phenylsulfanyl)quinolin-2(1H)-one
-
-
6-chloro-4-(phenylsulfinyl)quinolin-2(1H)-one
-
-
6-chloro-4-(phenylsulfonyl)quinolin-2(1H)-one
-
-
6-chloro-4-phenoxyquinolin-2(1H)-one
-
-
6-chloro-4-phenylquinolin-2(1H)-one
-
-
6-chloro-4-[(3,5-dimethylphenyl)sulfanyl]quinolin-2(1H)-one
-
-
6-chloro-4-[(3,5-dimethylphenyl)sulfinyl]quinolin-2(1H)-one
-
-
6-chloro-4-[(3,5-dimethylphenyl)sulfonyl]-3,4-dihydroquinoxalin-2(1H)-one
-
-
6-chloro-4-[(3,5-dimethylphenyl)sulfonyl]quinolin-2(1H)-one
-
-
9,10-dioxo-2-(2-oxo-2-phenylethoxy)-9,10-dihydroanthracen-1-yl acetate
-
-
9,10-dioxo-2-(2-oxopropoxy)-9,10-dihydroanthracen-1-yl acetate
-
noncompetitive inhibitor, KNA-53 inhibits the RNase H function and is inactive on the polymerase function of enzyme mutant Y181C
9,10-dioxo-2-(prop-2-en-1-yloxy)-9,10-dihydroanthracen-1-yl acetate
-
-
9,10-dioxo-2-(prop-2-yn-1-yloxy)-9,10-dihydroanthracen-1-yl acetate
-
-
9,10-dioxo-2-[(2-oxopentan-3-yl)oxy]-9,10-dihydroanthracen-1-yl acetate
-
-
9,10-dioxo-2-[(3-oxobutan-2-yl)oxy]-9,10-dihydroanthracen-1-yl acetate
-
-
9,10-dioxo-9,10-dihydroanthracene-1,2-diyl diacetate
-
-
9,10-dioxo-9,10-dihydroanthracene-1,2-diyl dibenzoate
-
noncompetitive inhibitor
9-(pyridin-3-yl)-1,7,9,10,11,12-hexahydro-3,2-(metheno)-10-azaazuleno[1',8',7',6':3,4,5]cyclopenta[6,7]fluoreno[2,1,9,8-fghij]benzo[cd]cyclopenta[mno]acephenanthrylene-11-carboxylic acid
-
pyridine fullerene derivative, 50% cytotoxicity above 0.05 mM
alpha-amomeric oligonucleotides
-
inhibit reaction with either homopolymeric or heteropolymeric substrates
-
alpha-d(A)15
-
0.032 mM, inhibits 50% of the RNA dependent DNA polymerase activity, reaction with poly(U) as template
-
alpha-d(T)16
-
0.08 mM, 50% inhibition of RNA dependent DNA polymerase activity when 0.0075 mM beta-pd(T)12-18 as primer, poly(A) as template
-
azidothymidine triphosphate
-
-
capravirine
-
HIV reverse transcriptase contains two distinct protein domains catalyzing DNA polymerase and RNase H activities. Inhibits 5'-RNA directed HIV RNase H activity of reverse transcriptase. Potency of RNase H inhibition correlats with the respective potencies of DNA polymerase inhibition
dATP
-
replacement of dATP by ATP completely prevents synthesis
ddTTP
-
inhibits the enzyme from the group M strain BH10 isolate and the enzyme from the Spanish HIV-1 group O isolate
Dextran sulfate
-
IC50: 0.0044 mg/ml
-
early growth response-1
-
overexpressio nof early growth response-1 decreases TERT protein production as well TERT mRNA transcription
-
emetine
-
plant alkaloid isolated from Psychotria ipecacuanha. Reverse transcriptase is blocked in the presence of emetine both both in in vitro reactions with isolated enzyme and intravirion, reaching 80% of reduction in HIV-1 infection, with low cytotoxic effect. Emetine also blocks HIV-1 infection of reverse transcriptase M184V mutants
flavanonol
-
low inhibition
GW8248
-
HIV reverse transcriptase contains two distinct protein domains catalyzing DNA polymerase and RNase H activities. Inhibits 5'-RNA directed HIV RNase H activity of reverse transcriptase. Potency of RNase H inhibition correlats with the respective potencies of DNA polymerase inhibition
heparin
-
IC50: 0.0740 mg/ml
Hygrophorus russula RNase
-
RNase isolated from fruiting bodies of the edible mushroom Hygrophorus russula inhibits reverse transcriptase by 91.6% at the concentration of 2.4 mg/ml
-
loviride
-
IC50: 0.0082-0.16 mM, depending on the substrate used.The enzyme from the group M strain BH10 isolate is sensitive. The enzyme from the Spanish HIV-1 group O isolate shows high-level resistance with IC50 above 0.2 mM
Mg2+
-
above 0.5 mM. Addition of Mg2+ to a reaction mixture that already contains Mn2+ does not inhibit the Mn2+-dependent synthesis
morpholinocytosine triphosphate
-
-
N-(4-chlorophenyl)acetamide
-
-
N-cyclobutyladenosine triphosphate
-
-
N-cyclobutyladenosine-phosphonyl diphosphate
-
-
N-methylisatin beta-thiosemicarbazone
-
0.4 mM, 88% inhibition with a 70S RSV RNA template-primer and 50% inhibition with a calf thymus DNA template-primer in the presence of 1% 2-mercaptoethanol
N-[4-[(4-[[4-(4-cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl]amino]piperidin-1-yl)methyl]phenyl]methanesulfonamide
-
-
N2-benzylguanine
-
the enzyme is strongly blocked, ethyl or larger groups cause preferential misincorporation and strong blockage of replicative polymerase activity
N2-ethylguanine
-
the enzyme is strongly blocked, ethyl or larger groups cause preferential misincorporation and strong blockage of replicative polymerase activity
N2-isobutylguanine
-
the enzyme is strongly blocked, ethyl or larger groups cause preferential misincorporation and strong blockage of replicative polymerase activity
N2-methyl(9-anthracenyl)guanine
-
the enzyme is strongly blocked, ethyl or larger groups cause preferential misincorporation and strong blockage of replicative polymerase activity
naldixic acid
-
noncompetitive with respect to TTP and polyriboadenylic acid. Inhibitory effect is higher with polyriboadenylic acid than with polyribocytidylic acid as a synthetic substrate
p-mercuribenzoate
-
0.02 mM, 96% loss of activity
phosphate
-
5 mM, reduced to 73% of maximal activity. 40 mM, reduced to 14% of maximal activity
PHP protein
-
a dimeric 16 kDa antifungal protein, isolated from the seeds of Peganum harmala by cationic exchange chromatography and gel filtration, inhibitor isoelectric point is about 8.4. Inhibits the viral polymerase to 69.1%. The protein has also inhibitory effect on cell proliferation and fungal growth, overview
-
propan-2-yl 7-methoxy-2-[(methylsulfanyl)methyl]-3-thioxo-3,4-dihydroquinoxaline-1(2H)-carboxylate
-
-
RNA aptamer
-
RNA aptamers suppress viral replication by cumulative inhibition of reverse transcriptase at every stage of genome replication
-
Streptonigrin
-
acts on the enzyme molecule in an enzyme-template primer complex by a series of reactions including oxidation-reduction
TMC-125
-
HIV reverse transcriptase contains two distinct protein domains catalyzing DNA polymerase and RNase H activities. Inhibits 5'-RNA directed HIV RNase H activity of reverse transcriptase. Potency of RNase H inhibition correlats with the respective potencies of DNA polymerase inhibition
TMC278
nonnucleoside reverse transcriptase inhibitor
zidovudine triphosphate
-
-
2',3'-dehydro-2',3'-deoxythymidine triphosphate
-
i.e. stavudine triphosphate
2',3'-dehydro-2',3'-deoxythymidine triphosphate
i.e. stavudine triphosphate
2',3'-dideoxy-2',3'-dehydrothymidine 5'-triphosphate
-
terminates synthesis of DNA
2',3'-dideoxy-2',3'-dehydrothymidine 5'-triphosphate
-
terminates synthesis of DNA
2',3'-dideoxythymidine 5'-triphosphate
-
-
2',3'-dideoxythymidine 5'-triphosphate
-
Mn2+ is requisite for the compound to exhibit inhibition, competitive with dTTP
3'-Azido-2',3'-dideoxythymidine 5'-triphosphate
-
inhibits the enzyme from the group M strain BH10 isolate and the enzyme from the Spanish HIV-1 group O isolate
3'-Azido-2',3'-dideoxythymidine 5'-triphosphate
-
-
3'-Azido-2',3'-dideoxythymidine 5'-triphosphate
-
most potent and selective inhibitor
3'-Azido-2',3'-dideoxythymidine 5'-triphosphate
-
Mn2+ is requisite for the compound to exhibit inhibition, competitive with dTTP
3'-azido-3'-deoxythymidine
-
-
3'-azido-3'-deoxythymidine
-
-
3'-azido-3'-deoxythymidine
-
3'-azido-3'deoxythymidine 5'-triphosphate
-
IC50: 0.042 mM
3'-azido-3'deoxythymidine 5'-triphosphate
-
IC50: 0.06 mM
4'-ethynyl-2-amino-2'-deoxyadenosine triphosphate
-
-
4'-ethynyl-2-amino-2'-deoxyadenosine triphosphate
-
4'-ethynyl-2-fluoro-2'-deoxyadenosine triphosphate
-
-
4'-ethynyl-2-fluoro-2'-deoxyadenosine triphosphate
-
6-([4-[(4-cyanophenyl)amino]-1,3,5-triazin-2-yl]amino)-5,7-dimethylnaphthalene-2-carbonitrile
-
compound has potency below 10 nM towards wild-type HIV-1 and viral variants containing the clinically important Y181C and K103N/Y181C mutations, greater activity than efavirenz particularly towards the K103N-bearing variant, normal cytotoxicity, and solubility
6-([4-[(4-cyanophenyl)amino]-1,3,5-triazin-2-yl]amino)-5,7-dimethylnaphthalene-2-carbonitrile
i.e. F3284-8495, a specific inhibitor of reverse transcriptase RNase H, with low micromolar potency in vitro
adefovir diphosphate
-
-
azidothymidine
prototype foamy virus
-
inhibits foamy virus replication
azidothymidine
-
inhibits FV replication
ddATP
-
0.015 mM
ddATP
-
competitive with respect to dATP, noncompetitive with respect to dCTP, dGTP and dTTP
Delavirdine
-
-
didanosine
-
-
efavirenz
-
-
efavirenz
-
HIV reverse transcriptase contains two distinct protein domains catalyzing DNA polymerase and RNase H activities. Inhibits 5'-RNA directed HIV RNase H activity of reverse transcriptase. Potency of RNase H inhibition correlats with the respective potencies of DNA polymerase inhibition
efavirenz
-
efavirenz actually stimulates wild type RNase H binding and catalytic functions, stimulating both 3' and 5'-directed RNase H activity. Efavirenz specifically promotes binding of the reverse transcriptase to RNase H substrates
efavirenz
-
Compound has no effect on polymerase-dependent RNase H cleavages but significantly affects the rates of polymerase-independent RNase H cleavages. Efavirenz destabilizes the 3'-end of the DNA primer in the DNA polymerase active site and promotes RT-mediated polymerase-independent cleavages
efavirenz
-
antiviral potency, EC50: 0.000001 mM
Etravirine
-
-
KCl
-
80 mM, 50% inhibition
KCl
-
80 mM, 60% inhibition
lamivudine
-
-
lamivudine triphosphate
-
-
lamivudine triphosphate
-
-
lamivudine triphosphate
-
Mn2+
-
above 1 mM MnCl2
NEM
-
-
NEM
-
2 mM, 82% loss of activity
nevirapine
-
-
nevirapine
-
the enzyme from the group M strain BH10 isolate is sensitive, the enzyme from the Spanish HIV-1 group O isolate shows high-level resistance with IC50 above 0.2 mM
nevirapine
-
HIV reverse transcriptase contains two distinct protein domains catalyzing DNA polymerase and RNase H activities. Inhibits 5'-RNA directed HIV RNase H activity of reverse transcriptase. Potency of RNase H inhibition correlats with the respective potencies of DNA polymerase inhibition
nevirapine
-
neviparine is 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
nevirapine
-
antiviral potency, EC50: 0.00004 mM
Rilpivirine
-
-
stavudine
-
potent inhibitor
suramin
-
-
Tenofovir
-
-
Tenofovir
-
9-[(2-phosphonomethoxy)propyl]adenine
tenofovir diphosphate
-
-
tenofovir diphosphate
-
-
zidovudine
-
-
additional information
-
not inhibited by didanosine, lamivudine, stavudine, and zidovudine
-
additional information
-
inhibition of feline immunodeficiency virus proviral DNA synthesis is not observed in cells expressing short hairpin RNA that targets the gag gene of feline immunodeficiency virus
-
additional information
-
the anti-HIV-1 effect of glycyrrhetinic acid may be involved in the selective inhibition of the human casein kinase II mediated stimulation of HIV-1 RT at the cellular level
-
additional information
-
inhibitors of reverse transcriptase belong to two main classes acting by distinct mechanisms. Nucleoside inhibitors of reverse transcriptase lack a 3' hydroxyl group on their ribose or ribose mimic moiety and thus act as chain terminators. Non-nucleoside inhibitors of reverse transcriptase bind into a hydrophobic pocket close to the polymerase active site and inhibit the chemical step of the polymerization reaction
-
additional information
-
heat shock perturbes owl monkey TRIMCyp and rhesus TRIM5alpha-mediated restriction of human immunodeficiency virus type 1 late reverse trans products and 2-long terminal repeat circles
-
additional information
-
alizarine derivatives as dual inhibitors of the HIV-1 reverse transcriptase-associated DNA polymerase and RNase H activities effective also on the RNase H activity of non-nucleoside resistant reverse transcriptases, molecular docking and molecular dynamic simulation, overview
-
additional information
-
N-cyclobutyladenosine analogues can act as substrates for incorporation by HIV-1 RT and be a potential scaffold for HIV inhibitors, cyclobutyl derivatives of 2-deoxyadenosine 5-triphosphate as inhibitors of HIV-1 reverse transcriptase, overview
-
additional information
-
inhibitor structure-activity relationships, overview
-
additional information
-
nucleoside reverse transcriptase inhibitors mimic the natural dNTP substrate of the enzyme and bind to the 3'-primer terminus in the polymerase active site acting as chain terminators. A lack of a 3'-OH group promotes effective chain termination, but it also imparts a negative effect on the potency of the NRTI, including a diminished binding affinity for the RT target and decreased ability to be activated by cellular kinases. nucleoside reverse transcriptase inhibitors with 4'-substitutions and a 3'-OH are very effective at inhibiting both wild-type and multi-drug resistant strains of HIV, structure-function analysis, overview
-
additional information
-
ribonucleoside chain terminators may be a class of anti-HIV-1 agents specifically targeting viral macrophage infection
-
additional information
-
synthesis and inhibitory potencies of pyridone diaryl ether non-nucleoside inhibitors of HIV-1 reverse transcriptase, structure-based drug design, overview
-
additional information
-
synthesis and inhibitory activities of quinolin-2-one alkaloid derivatives against HIV-1 reverse transcriptase, molecular docking study, overview
-
additional information
-
EC50 values, molecular modeling, overview
-
additional information
AF324493
comparison of inhibitor susceptibilities of HIV-1 subtype B and subtype C recombinant reverse transcriptases, overview; comparison of inhibitor susceptibilities of HIV-1 subtype B and subtype C recombinant reverse transcriptases, overview; comparison of inhibitor susceptibilities of HIV-1 subtype B and subtype C recombinant reverse transcriptases, overview
-
additional information
comparison of inhibitor susceptibilities of HIV-1 subtype B and subtype C recombinant reverse transcriptases, overview; comparison of inhibitor susceptibilities of HIV-1 subtype B and subtype C recombinant reverse transcriptases, overview; comparison of inhibitor susceptibilities of HIV-1 subtype B and subtype C recombinant reverse transcriptases, overview
-
additional information
comparison of inhibitor susceptibilities of HIV-1 subtype B and subtype C recombinant reverse transcriptases, overview; comparison of inhibitor susceptibilities of HIV-1 subtype B and subtype C recombinant reverse transcriptases, overview; comparison of inhibitor susceptibilities of HIV-1 subtype B and subtype C recombinant reverse transcriptases, overview
-
additional information
-
comparison of inhibitor susceptibilities of HIV-1 subtype B and subtype C recombinant reverse transcriptases, overview; comparison of inhibitor susceptibilities of HIV-1 subtype B and subtype C recombinant reverse transcriptases, overview; comparison of inhibitor susceptibilities of HIV-1 subtype B and subtype C recombinant reverse transcriptases, overview
-
additional information
-
simultaneous presence of free hydroxyl groups at position 3 and 4' enhance the reverse transcriptase inhibitory activity. Replacement of the 3-hydroxyl group with a monosaccharide or of the 4'-hydroxyl group with a Me group reduces inhibitory activity. The double bond at position 2 and 3 of the flavonoids pyrone ring is not essential for inhibiting reverse transcriptase activity
-
additional information
-
the enzyme is highly susceptible to some nucleoside RT inhibitors, including translocation deficient RT inhibitors, but not to non-nucleoside RT inhibitors, e.g. TMC-125 and efavirenz, due to lack of two tyrosine residues involved in binding in enzymes from other virus
-
additional information
-
targeted disruption of aromatase results in significant inhibition of telomerase activity
-
additional information
-
decreased telomerase activity and normal expression of telomere-binding proteins in the absence of Dicer
-
additional information
the enzyme is highly susceptible to some nucleoside RT inhibitors, including translocation deficient RT inhibitors, but not to non-nucleoside RT inhibitors, e.g. TMC-125 and efavirenz, due to lack of two tyrosine residues involved in binding in enzymes from other virus
-
additional information
-
the enzyme is highly susceptible to some nucleoside RT inhibitors, including translocation deficient RT inhibitors, but not to non-nucleoside RT inhibitors, e.g. TMC-125 and efavirenz, due to lack of two tyrosine residues involved in binding in enzymes from other virus
-